IP Library › Granted Patent US 12,378,230
Granted Patent B2
US 12,378,230 · App. 18/483,311 · Granted Aug 5, 2025

GLP-1 receptor agonists and uses thereof

Inventors: Gary Erik Aspnes (Biberach an der Riss, DE); Scott W. Bagley (Voluntown, CT); John M. Curto (Mystic, CT); David James Edmonds (Riehen, CH); Mark E. Flanagan (Gales Ferry, CT); Kentaro Futatsugi (Sharon, MA); David A. Griffith (Sudbury, MA); Kim Huard (Berkeley, CA); Yajing Lian (Waterford, CT); Chris Limberakis (Pawcatuck, CT); Allyn T. Londregan (Barrington, RI); Alan M. Mathiowetz (Waltham, MA); David W. Piotrowski (Waterford, CT); Roger B. Ruggeri (Waterford, CT)
Assignee: Pfizer Inc.
C07D405/12C07C53/06C07C53/10C07C215/40C07D405/14C07D413/14C07D471/04C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,378,230
App. No.
18/483,311
Granted
Aug 5, 2025
Kind
B2
Abstract

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Claims (38)

1. A method for treating a disease or disorder in a human comprising administering to the human a compound, wherein the disease or disorder is selected from the group consisting of Type 2 diabetes mellitus (T2DM), pre-diabetes, latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), malnutrition-related diabetes, gestational diabetes, arthritis, osteoporosis, Parkinson's Disease, Alzheimer's Disease, addiction, addiction to alcohol abuse, addiction to drug abuse, sleep apnea, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, and metabolic syndrome; and wherein the compound is

2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-({4-[2-(4-chloro-2-fluorophenyl)-7-fluoro-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid;

2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; or

2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the compound is

2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 wherein the compound is 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

4. The method of claim 3 wherein the compound is a pharmaceutically acceptable salt of 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

5. A method for treating a disease or disorder in a human comprising administering to the human a compound, wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, malnutrition-related diabetes, gestational diabetes, arthritis, osteoporosis, Parkinson's Disease, Alzheimer's Disease, addiction, addiction to alcohol abuse, addiction to drug abuse, sleep apnea, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, and metabolic syndrome; and wherein the compound is

2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; or

2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 wherein the compound is 2-({4-[2-(4-chloro-2-fluorophenyl)-1, 3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

7. The method of claim 6 wherein the compound is a pharmaceutically acceptable salt of 2-({4-[2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

8. The method of claim 5 wherein the compound is 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 wherein the compound is a pharmaceutically acceptable salt of 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

10. A method for treating a disease or disorder in a human comprising administering to the human a compound, wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, malnutrition-related diabetes, gestational diabetes, arthritis, osteoporosis, sleep apnea, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, and metabolic syndrome; and wherein the compound is

2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; or

2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

11. The method of claim 10 wherein the compound is 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid or a pharmaceutically acceptable salt thereof.

12. The method of claim 10 wherein the compound is a pharmaceutically acceptable salt of 2-({4-[2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

13. A method for treating a disease or disorder in a human comprising administering to the human a compound, wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, malnutrition-related diabetes, gestational diabetes, arthritis, osteoporosis, Parkinson's Disease, Alzheimer's Disease, addiction, addiction to alcohol abuse, addiction to drug abuse, sleep apnea, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, and metabolic syndrome; and wherein the compound is 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 wherein the compound is a pharmaceutically acceptable salt of 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

15. The method of claim 14 wherein wherein the pharmaceutically acceptable salt is 1,3-dihydroxy-2-(hydroxymethyl) propan-2-amine salt (tris salt).

16. A method for treating a disease or disorder in a human comprising administering to the human a compound, wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, malnutrition-related diabetes, gestational diabetes, arthritis, osteoporosis, Parkinson's Disease, Alzheimer's Disease, addiction, addiction to alcohol abuse, addiction to drug abuse, sleep apnea, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, and metabolic syndrome; and wherein the compound is

2-({4-[2-(4-chloro-2-fluorophenyl)-7-fluoro-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid; or

2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

17. The method of claim 16 wherein the compound is 2-({4-[2-(4-chloro-2-fluorophenyl)-7-fluoro-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

18. The method of claim 17 wherein the compound is a pharmaceutically acceptable salt of 2-({4-[2-(4-chloro-2-fluorophenyl)-7-fluoro-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

19. The method of claim 16 wherein the compound is 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

20. The method of claim 19 wherein the compound is a pharmaceutically acceptable salt of 2-({4-[(2S)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-7-fluoro-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

Continuity (6)
Continuation 17171385 · Feb 9, 2021
Division 16436311 · Jun 10, 2019
Provisional Application 62851206 · May 22, 2019
Provisional Application 62846944 · May 13, 2019
Provisional Application 62684696 · Jun 13, 2018
Related Publication 20240059679A1 · Feb 22, 2024
References Cited (50)
US 5714498A · Kulagowski et al. · 1998 [cited by applicant]
US 6271241B1 · DeSimone et al. · 2001 [cited by applicant]
US 6362196B1 · Kulagowski · 2002 [cited by applicant]
US 6596722B2 · Moltzen et al. · 2003 [cited by applicant]
US 7160879B2 · DeSimone et al. · 2007 [cited by applicant]
US 7425554B2 · Kawahara et al. · 2008 [cited by applicant]
US 9351971B2 · Cardone et al. · 2016 [cited by applicant]
US 10676465B2 · Aspnes et al. · 2020 [cited by applicant]
US 10683281B2 · Aspnes et al. · 2020 [cited by applicant]
US 10934279B2 · Aspnes et al. · 2021 [cited by applicant]
US 20040077654A1 · Bouillot et al. · 2004 [cited by applicant]
US 20040127504A1 · Cowart et al. · 2004 [cited by applicant]
US 20070244133A1 · Bower et al. · 2007 [cited by applicant]
US 20080280933A1 · Efremov et al. · 2008 [cited by applicant]
US 20090227493A1 · Nakashima et al. · 2009 [cited by applicant]
US 20090281117A1 · Duffy et al. · 2009 [cited by applicant]
US 20110092415A1 · DeGoey et al. · 2011 [cited by applicant]
US 20150018363A1 · Kasai et al. · 2015 [cited by applicant]
US 20150376198A1 · Roberts et al. · 2015 [cited by applicant]
US 20170275279A1 · Buckner et al. · 2017 [cited by applicant]
US 20170349594A1 · Kim et al. · 2017 [cited by applicant]
US 20180305334A1 · Larsen et al. · 2018 [cited by applicant]
US 20190382384A1 · Aspnes et al. · 2019 [cited by applicant]
CA 2678687 · 2008 [cited by applicant]
CA 3038479 · 2018 [cited by applicant]
CN 102946882 · 2013 [cited by applicant]
EP 3239143 · 2017 [cited by applicant]
JP 2020200308 · 2020 [cited by applicant]
KR 20080089494 · 2008 [cited by applicant]
KR 20110052741 · 2011 [cited by applicant]
WO 2004013120 · 2004 [cited by applicant]
WO 2010048149 · 2010 [cited by applicant]
WO 2010114824 · 2010 [cited by applicant]
WO 2011097491 · 2011 [cited by applicant]
WO 2011143365 · 2011 [cited by applicant]
WO 2016107603 · 2016 [cited by applicant]
WO 2017068412 · 2017 [cited by applicant]
WO 2017161028 · 2017 [cited by applicant]
WO 2018056453 · 2018 [cited by applicant]
WO WO2018109607 · 2018 [cited by examiner]
WO 2022199661 · 2022 [cited by applicant]
WO 2022216094 · 2022 [cited by applicant]
Lopez-Rodriguez et al., “Design & synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands”, Bioorganic and Medicinal Chemistry Letters, vol. 13(9) pp. 3177-3180 (2003). [cited by applicant]
Lopez-Rodriguez et al.,“Benzimidazole derivatives. Part 5: Design & synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands”, Bioorganic and Medicinal Chemistry, vol. 12(19), pp. 5… [cited by applicant]
Compound 1; Chemical Abstracts Services (CAS): American Chemical Society, Columbus, Ohio, Aug. 6, 2017; Registry No. 2108925-34-2; Chemical name: (1R,4R)-rel-2-(1,3-benzodioxol-5-yl)-5-[(1-methyl-1H-benzimidazol-2-yl)me… [cited by applicant]
Compound 2; Chemical Abstracts Services (CAS): American Chemical Society, Columbus, Ohio, Jan. 23, 2014; Registry No. 1527580-20-6; Chemical name: (3R,4R)-rel-1-(1H-benzimidazol-2-ylmethyl)-4-(1,3-benzodioxol-5-yl)-3-pi… [cited by applicant]
Compound 3; Chemical Abstracts Services (CAS): American Chemical Society, Columbus, Ohio, Jan. 17, 2014; Registry No. 1523524-38-0; Chemical name: (3R,4R)-rel-4-(1,3-benzodioxol-5-yl)-1-[(1-methyl-1H-benzimidazol-2-yl)m… [cited by applicant]
PCT/IB2019/054867 International Search Report and Written Opinion dated Aug. 9, 2019. [cited by applicant]
Teng et al., “Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor”, Bioorganic & Medicinal Chemistry Letters, vol. 17(19), pp. 5472-5478 (2007). doi:10.1016/j.bmcl.2007.06.086. [cited by applicant]
“Livingston, et al.,. Chapter 19. Glucagon and Glucagon-Like Peptide-1, Annual Reports in Medicinal Chemistry, 189-198, (1999). doi: 10.1016/s0065-7743(08)60581-3”. [cited by applicant]
Cited By (1)
US 12,611,401